


HI5

Cat. No.:	HY-146261
CAS No.:	2411548-90-6
Molecular Formula:	C ₄₂ H ₄₃ N ₅ O ₈
Molecular Weight:	745.82
Target:	Microtubule/Tubulin; Indoleamine 2,3-Dioxygenase (IDO); Apoptosis
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HI5 is a potent tubulin and IDO inhibitor, with an IC ₅₀ value of 70 nM in HeLa cells. HI5 inhibit IDO expression and decrease kynurenine production, leading to stimulating T cells activation and proliferation. HI5 can inhibit tubulin polymerization and cell migration, cause G2/M phase arrest, and induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells. HI5 can be used for researching anticancer ^[1] .																
IC₅₀ & Target	IC ₅₀ : 70 nM in HeLa ^[1]																
In Vitro	<p>HI5 (0-10 μM; 72 hours) exhibits potent antiproliferative activity in HeLa, PC-3, A549 and HUVEC^[1].</p> <p>HI5 (0.1 and 0.5 μM; 24 hours) exhibits markedly disruption of microtubule organization in a concentration-dependent manner^[1].</p> <p>HI5 (0.5 μM; 24 hours) significantly up-regulates the expression level of Bax protein, while down-regulates the protein of Bcl-2, furthermore, markedly up-regulates the protein expressions of caspase-3 and PARP^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa, PC-3, A549 and HUVEC^[1]</td> </tr> <tr> <td>Concentration:</td> <td>0-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Exhibited potent antiproliferative activity in HeLa, PC-3, A549 and HUVEC with IC₅₀s of 0.07 ± 0.005 μM, 0.46 ± 0.06 μM, 0.22 ± 0.10 μM, 1.52 ± 0.09 μM, respectively.</td> </tr> </table> <p>Immunofluorescence</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa^[1]</td> </tr> <tr> <td>Concentration:</td> <td>0.1 and 0.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Exhibited markedly disruption of microtubule organization in a concentration-dependent manner.</td> </tr> </table>	Cell Line:	HeLa, PC-3, A549 and HUVEC ^[1]	Concentration:	0-10 μM	Incubation Time:	72 hours	Result:	Exhibited potent antiproliferative activity in HeLa, PC-3, A549 and HUVEC with IC ₅₀ s of 0.07 ± 0.005 μM, 0.46 ± 0.06 μM, 0.22 ± 0.10 μM, 1.52 ± 0.09 μM, respectively.	Cell Line:	HeLa ^[1]	Concentration:	0.1 and 0.5 μM	Incubation Time:	24 hours	Result:	Exhibited markedly disruption of microtubule organization in a concentration-dependent manner.
Cell Line:	HeLa, PC-3, A549 and HUVEC ^[1]																
Concentration:	0-10 μM																
Incubation Time:	72 hours																
Result:	Exhibited potent antiproliferative activity in HeLa, PC-3, A549 and HUVEC with IC ₅₀ s of 0.07 ± 0.005 μM, 0.46 ± 0.06 μM, 0.22 ± 0.10 μM, 1.52 ± 0.09 μM, respectively.																
Cell Line:	HeLa ^[1]																
Concentration:	0.1 and 0.5 μM																
Incubation Time:	24 hours																
Result:	Exhibited markedly disruption of microtubule organization in a concentration-dependent manner.																

	Western Blot Analysis
Cell Line:	HeLa ^[1]
Concentration:	0.5 μ M
Incubation Time:	24 hours
Result:	Significantly up-regulated the expression level of Bax protein, while down-regulated the protein of Bcl-2, furthermore, markedly up-regulated the protein expressions of caspase-3 and PARP.
In Vivo	<p>HI5 (15 and 30 mg/kg; IV; daily, for 21 days) significantly inhibits tumor growth at a dose-dependent manner^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
Animal Model:	BALB/c nude mice (18-22 g, 5 week-old, injected with HeLa cells) ^[1]
Dosage:	15 and 30 mg/kg
Administration:	IV; daily, for 21 days
Result:	Significantly inhibited tumor growth at a dose-dependent manner with inhibitory rates of 50.73% and 65.76% at doses of 15 and 30 mg/kg, respectively.

REFERENCES

[1]. Hua S, et al. Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase. *Eur J Med Chem.* 2020;189:112041.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA